Valencia

• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting
  2023-509673-22-00 9 2024-12-02 Neuroblastoma
• A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting
  2024-514177-21-00 4 2024-12-02 Solid tumours
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 4 2024-11-27 MMRp/ MSS colon cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Recruiting
  2024-511838-12-00 3 2024-11-22 Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated … Recruiting
  2024-514446-36-00 1 2024-11-21 Small Cell Lung Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Use of statins in patients with intracerebral hemorrhage Recruiting
  2024-511465-11-00 5 2024-11-20 Spontaneous lobar ICH
• LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat … Recruiting
  2024-512835-53-00 4 2024-11-20 Diffuse Large B-Cell Lymphoma
• Randomised, double-blind, multicentre, phase III clinical trial to evaluate the efficacy and safety of dexamethasone compared to placebo in … Recruiting
  2024-513209-30-00 5 2024-11-20 Severe Influenza
• A Phase IV, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Almagate in Pregnant Women With Heartburn and Reflux, and Pe … Recruiting
  2024-515381-14-00 6 2024-11-20 heartburn and or reflux
• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 7 2024-11-14 Advance solid tumors
• Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting
  2024-516011-24-01 4 2024-11-13 Cytomegalovirus infection in allogeneic stem cell transplant recipient
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Pa … Recruiting
  2023-507178-41-00 9 2024-11-07 Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia Recruiting
  2023-510288-37-00 3 2024-11-01 Relapsed and/or refractory Acute Myeloid Leukemia

Showing 625–648 of 1,853 trials